Syngene International Ltd

Syngene Intl. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Syngene International Ltd

₹ 639 0.73%
21 Nov 12:07 p.m.
syngeneintl.com BSE: 539268 NSE: SYNGENE
About

Syngene (established in 1993) as a Biocon subsidiary is India's first Contract Research Organization (CRO) which expanded later to be an integrated service provider offering end-to-end drug discovery, development, and manufacturing services on a single platform (CRAMS). Total research & manufacturing infrastructure for the company is spread across 1.9 million square feet across locations. [1]

Key Points

Business Footprint:[1]
The company caters to diverse end-user industries like Pharmaceuticals, Animal Health, Agrochemicals, Consumer Packaged Goods, Chemicals/Polymers.
It has 400+ active customers with engagements with 13 out of the top 15 global pharma companies. The company holds 400+ patents jointly with clients and has a base of 6000+ scientists.

Website BSE NSE
  • Market Cap ₹ 25,754 Cr.
  • Current Price ₹ 639
  • High / Low ₹ 961 / 599
  • Stock P/E 55.0
  • Book Value ₹ 118
  • Dividend Yield 0.20 %
  • ROCE 13.5 %
  • ROE 10.5 %
  • Face Value ₹ 10.0
Edit ratios

Pros

Cons

  • Stock is trading at 5.42 times its book value
  • Company has a low return on equity of 12.3% over last 3 years.
  • Dividend payout has been low at 10.3% of profits over last 3 years
  • Promoter holding has decreased over last 3 years: -12.2%

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Healthcare Services Healthcare Research, Analytics & Technology

Part of BSE 500 BSE Healthcare Nifty 500 BSE SmallCap BSE Allcap

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025
768 786 994 808 910 854 917 790 891 944 1,018 874 911
552 555 680 596 656 622 600 620 646 660 674 668 711
Operating Profit 216 231 314 212 254 232 317 170 245 284 344 206 200
OPM % 28% 29% 32% 26% 28% 27% 35% 22% 27% 30% 34% 24% 22%
15 17 23 24 14 26 16 50 16 18 19 18 15
Interest 12 14 10 10 13 11 13 12 13 12 16 12 13
Depreciation 90 95 96 102 105 108 111 107 111 109 106 111 116
Profit before tax 130 140 231 123 151 138 209 101 137 181 240 101 85
Tax % 22% 22% 23% 24% 23% 19% 10% 25% 23% 27% 24% 14% 21%
102 110 179 93 116 112 189 76 106 131 183 87 67
EPS in Rs 2.54 2.73 4.45 2.32 2.90 2.77 4.69 1.88 2.64 3.26 4.55 2.15 1.67
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
1,423 1,826 2,012 2,184 2,604 3,193 3,489 3,642 3,747
949 1,289 1,394 1,507 1,806 2,251 2,472 2,598 2,714
Operating Profit 474 537 618 678 798 942 1,017 1,045 1,033
OPM % 33% 29% 31% 31% 31% 30% 29% 29% 28%
53 75 153 94 20 63 77 101 70
Interest 23 32 35 28 24 45 47 53 53
Depreciation 131 164 219 274 310 366 426 433 442
Profit before tax 372 415 517 469 484 594 621 660 608
Tax % 18% 20% 20% 14% 18% 22% 18% 25%
305 332 412 405 396 464 510 496 468
EPS in Rs 7.64 8.29 10.30 10.12 9.88 11.57 12.69 12.33 11.63
Dividend Payout % 7% 3% 0% 0% 10% 11% 10% 10%
Compounded Sales Growth
10 Years: %
5 Years: 13%
3 Years: 12%
TTM: 9%
Compounded Profit Growth
10 Years: %
5 Years: 6%
3 Years: 4%
TTM: 2%
Stock Price CAGR
10 Years: 13%
5 Years: 2%
3 Years: 2%
1 Year: -25%
Return on Equity
10 Years: %
5 Years: 13%
3 Years: 12%
Last Year: 11%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Sep 2025
Equity Capital 200 200 400 400 401 401 402 402 403
Reserves 1,520 1,768 1,776 2,421 2,897 3,217 3,856 4,324 4,332
787 813 773 893 1,022 815 555 578 582
681 922 1,214 1,169 1,245 1,398 1,339 1,491 1,226
Total Liabilities 3,189 3,704 4,163 4,883 5,564 5,831 6,152 6,796 6,542
1,030 1,377 2,020 2,201 2,393 2,667 2,850 2,802 3,049
CWIP 155 274 234 237 346 177 838 1,266 989
Investments 158 716 776 702 1,034 918 548 647 547
1,846 1,337 1,133 1,743 1,790 2,069 1,916 2,081 1,957
Total Assets 3,189 3,704 4,163 4,883 5,564 5,831 6,152 6,796 6,542

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
446 630 677 701 581 824 1,042 1,168
-349 -646 -424 -629 -611 -653 -494 -744
-79 -72 -226 58 -31 -342 -551 -142
Net Cash Flow 18 -88 28 130 -62 -172 -4 281

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 68 68 72 79 71 61 46 53
Inventory Days 82 30 18 41 87 141 94 60
Days Payable 195 154 156 167 113 109 100 136
Cash Conversion Cycle -44 -56 -66 -47 45 92 40 -23
Working Capital Days -48 -103 -172 -66 -43 -14 -27 -51
ROCE % 17% 17% 14% 13% 15% 15% 14%

Shareholding Pattern

Numbers in percentages

Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025
64.86% 54.88% 54.80% 54.79% 54.79% 54.79% 54.72% 54.72% 52.74% 52.74% 52.68% 52.68%
16.87% 23.31% 23.19% 23.55% 21.20% 20.92% 20.64% 20.72% 20.65% 19.47% 16.51% 16.31%
7.03% 10.71% 11.20% 11.70% 14.63% 15.80% 16.78% 17.49% 19.52% 21.50% 24.05% 24.62%
10.77% 10.65% 10.23% 9.47% 9.07% 8.18% 7.44% 6.74% 6.79% 5.99% 6.45% 6.08%
0.47% 0.46% 0.60% 0.48% 0.32% 0.31% 0.43% 0.34% 0.29% 0.29% 0.31% 0.30%
No. of Shareholders 1,27,9641,24,0141,25,4551,25,9921,21,8801,15,8501,20,0181,07,3381,28,8061,25,0901,42,3101,36,061

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls